CSPG4 overexpression

CSPG4 overexpression in diverse tumors and its correlation with adverse prognostic outcomes emphasize its significance in cancer biology. These findings suggest that targeting CSPG4 offers a promising avenue for future cancer therapy, with potential synergistic effects when combined with existing treatments.

The vaccination resulted clinically effective; vaccinated dogs had a prolonged overall survival as compared to conventionally treated controls. Finally, HuDo-CSPG4 induced a cytotoxic response in a human surrogate setting.ConclusionOverall, based on these findings and considering the high predictive value of spontaneous canine tumors, these results might route the potential translation of this novel immunotherapeutic approach into a human setting.

CSPG4 overexpression conferred resistance to doxorubicin, suggesting that CSPG4 immuno-targeting could sensitize OSA cells to chemotherapy...In vaccinated dogs, the induction of both anti-CSPG4 humoral and cellular response have been observed. Conclusion Overall, considering the high predictive value of spontaneous canine tumors, these results will possibly route the translation of this novel immunotherapeutic approach into a human setting, eventually improving life expectancy of OSA patients that cannot benefit from present therapies.

CSPG4 expression is significantly elevated in aggressive thyroid cancers, with a strong correlation with a poor prognosis. The vast number of HLA-DQ eluted CSPG4 peptides was identified in ATC, demonstrating the potential of CSPG4 as a novel immunotherapeutic target for ATC.

Further investigations could provide more insights toward the understanding of the immune response triggered by vaccination and its possible effect on prolonging the survival of canine patients. Conclusion In the future, these findings could be translated in a human clinical setting, hopefully improving life expectancy of OSA patients that cannot benefit from present therapies.

Further investigations could provide more insights toward the understanding of the immune response triggered by vaccination and its possible effect on prolonging the survival of canine patients. Conclusion In the future, these findings could be translated in a human clinical setting, hopefully improving life expectancy of OSA patients that cannot benefit from present therapies.

Further investigations could provide more insights toward the understanding of the immune response triggered by vaccination and its possible effect on prolonging the survival of canine patients. Conclusion In the future, these findings could be translated in a human clinical setting, hopefully improving life expectancy of OSA patients that cannot benefit from present therapies.

Further investigations could provide more insights toward the understanding of the immune response triggered by vaccination and its possible effect on prolonging the survival of canine patients. Conclusion In the future, these findings could be translated in a human clinical setting, hopefully improving life expectancy of OSA patients that cannot benefit from present therapies.

Conclusion These results provide the rationale to propose HuDo-CSPG4 vaccination for the treatment of canine CSPG4+ tumors. Thanks to the power of naturally occurring cancers in dogs as valuable predictive models for cancer immunotherapy response, these data represent a solid basis to stimulate the translation of this approach in a human clinical setting.

Conclusion These results provide the rationale to propose HuDo-CSPG4 vaccination for the treatment of canine CSPG4+ tumors. Thanks to the power of naturally occurring cancers in dogs as valuable predictive models for cancer immunotherapy response, these data represent a solid basis to stimulate the translation of this approach in a human clinical setting.

Conclusion These results provide the rationale to propose HuDo-CSPG4 vaccination for the treatment of canine CSPG4+ tumors. Thanks to the power of naturally occurring cancers in dogs as valuable predictive models for cancer immunotherapy response, these data represent a solid basis to stimulate the translation of this approach in a human clinical setting.

Conclusion These results provide the rationale to propose HuDo-CSPG4 vaccination for the treatment of canine CSPG4+ tumors. Thanks to the power of naturally occurring cancers in dogs as valuable predictive models for cancer immunotherapy response, these data represent a solid basis to stimulate the translation of this approach in a human clinical setting.

Further investigations could provide more insights toward the understanding of the immune response triggered by vaccination and its possible effect on prolonging the survival of canine patients. Conclusion In the future, these findings could be translated in a human clinical setting, hopefully improving life expectancy of OSA patients that cannot benefit from present therapies.